Allison Whitten on Muck Rack

Allison Whitten

Verified
Nashville
As seen in: DDNews, Stanford University, WIRED (UK), WIRED Magazine, Ars Technica, Phys.org, Medical Xpress, Discover Magazine, Quanta Magazine, Astronomy Magazine, Genetic Literacy Project and
Assistant Editor @DrugDiscovNews. PhD @VanderbiltU. Past @AAASMassMedia @DiscoverMag @QuantaMagazine. Fan of @UMichFootball.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Allison

Contact Allison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA priority vouchers for GLP-1 drugs could quickly bring oral version, higher dose

|
By Allison Whitten Verified
| DDNews Verified
This article is part of our series on the FDA’s National Priority Voucher program, exploring the therapies selected, their potential impact, safety considerations, and what accelerated review could mean for patients in the US and globally. In November 2025, the FDA announced the addition of six more awardees under the Commissioner’s National Priority Voucher program. The voucher allows companies to receive a decision on their product in just one to two months compared to the usual 10–12 months.
Open in Who Shared Issue with article?

Blood tests for colorectal cancer screening have arrived

|
By Allison Whitten Verified
| DDNews Verified
Over the last several decades, a new mystery has emerged surrounding the rates of colorectal cancer (CRC). In people over 65, rates have been dropping, but they are steadily rising in younger adults — with the fastest rise happening in those under 55. In 2019, adults 54 and younger made up 20 percent of new CRC cases, compared to 11 percent in 1995 . “It's still a largely unanswered question.
Open in Who Shared Issue with article?

Long-awaited results of GLP-1 trial in Alzheimer’s disease show disappointing results

|
By Allison Whitten Verified
| DDNews Verified
After GLP-1 drugs revolutionized the treatment of type 2 diabetes and obesity, it started to look like there was nothing they couldn’t treat. A deluge of new clinical trials popped up to test whether the new class of drugs could treat conditions that ranged from addiction, obstructive sleep apnea, and chronic kidney disease.
Open in Who Shared Issue with article?
See all 130 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified